Dear Friends of TAG:

I’m very happy to present TAG’s annual report for 2012. As you will read in these pages, there were many new developments in the fields of HIV/AIDS, hepatitis C virus (HCV), and tuberculosis (TB).

As we continued our fight in 2012 to ensure treatment access as well as prevention and care for all who need it, we worked with scientists, activists, researchers, governments, policy makers, and other key stakeholders to continue to accelerate the science that changes and ultimately saves lives.

We are grateful for your continued support, which enables us in our critical advocacy and activism. We look to this year with cautious optimism and great resolve as we work to ensure that people with HIV/AIDS, HCV, and TB receive the lifesaving treatment, care, and information they need.

Sincerely,

Barbara Hughes
President, Board of Directors
2012 Research in Action Awards

TAG’s Research in Action Awards (RIAA) honor activists, scientists, philanthropists, and creative artists who have made extraordinary contributions in the fight against AIDS. RIAA is a fundraiser to support TAG’s programs and provides a forum to honor heroes of the epidemic.

The 2012 Research in Action Awards, which marked the 20th anniversary of TAG’s founding, were celebrated on December 9 at 404, on 10th Avenue and 33rd Street. Jenna Wolfe, weekend anchor on NBC’s Today Show, hosted the event.

2012 RIAA honorees:

Dr. Françoise Barré-Sinoussi is the virologist who, in 1983, discovered HIV and in 2008 won the Nobel Prize for that discovery. She is president of the International AIDS Society (IAS), has authored hundreds of scientific publications, and leads the IAS’s Global Scientific Strategy: “Towards an HIV Cure.”

Jon Cohen is an AIDS journalist for Science magazine and author of Shots in the Dark, a stirring and thorough account of the search for an AIDS vaccine in the earlier days of the epidemic that still serves as a wake-up call for the work that must be done to finally end AIDS.

Dr. Paul Farmer is cofounder of Partners In Health and chairman of Harvard Medical School’s Department of Global Health and Social Medicine. His vision and leadership were critical to the movement to make AIDS treatments available to those in the developing world. His work was heralded in Tracy Kidder’s hugely popular Mountains Beyond Mountains: The Quest of Dr. Paul Farmer, a Man Who Would Cure the World.

Judith Light is an Emmy- and Tony Award–winning actress renowned not only for her career in theater, film, and television, but also for her passionate and longtime advocacy for organizations and charities representing AIDS-related and human rights issues, including Broadway Cares/Equity Fight AIDS, the Names Project, the AIDS Memorial Quilt, Project Angel Food, and the Trevor Project.

See video highlights from the 2012 Research in Action Awards at: www.treatmentactiongroup.org/riaa.

TAG Limited Art Edition

Acclaimed artist Robert Gober generously donated a limited edition of 20 woodblock prints, which he created especially for TAG.

Gober has exhibited widely throughout the U.S., Europe, and Japan, and his work is held in major museum collections, including the Whitney Museum of Art, the Guggenheim Museum, the San Francisco Museum of Modern Art, the Tate Modern, and many others. In 2014, there will be a 30-year survey of his work at the Museum of Modern Art in New York. Robert Gober is represented by the Matthew Marks Gallery in New York City: www.matthewmarks.com/new-york/artists/robert-gober/.
**TAG PROGRAMS**

**An AIDS-Free Generation?**

Significant HIV treatment and prevention advances over the past several years reached a tipping point in 2012, notably at July’s International AIDS Conference in Washington, D.C., where numerous governmental and non-governmental leaders declared that we now have the tools to achieve an “AIDS-free generation.” This aspiration was buttressed by former secretary of state Hillary Clinton’s pre–World AIDS Day release of the Obama administration’s ambitious PEPFAR Blueprint: Creating an AIDS-Free Generation.

While TAG applauded the Blueprint for reinforcing that the United States’ global commitment remains strategic and driven by science, we recognized that the plan far surpassed those in place to achieve domestic targets, as specified in the 2010 White House release of the National HIV/AIDS Strategy (NHAS). In turn, TAG fortified its efforts in 2012 to end the inertia on HIV/AIDS in the United States, where more than 15,000 people with an AIDS diagnosis still die each year, and new HIV infection rates remain around 50,000 annually.

In December, TAG convened a meeting of HIV activists, service providers, and researchers to address glaring disparities in the U.S. treatment cascade, which begins with only 80 percent of those with HIV being aware of their status and ends with only one in four being effectively treated with antiretroviral therapy. A key advocacy priority borne out of the meeting was the development of an evidence-based research and implementation science agenda to ensure that policy and care programs to address these gaps are based on sound data, particularly within the context of implementation of the Affordable Care Act, Medicaid expansion, and the uncertain future of Ryan White CARE Act funding.

A meeting report and action plan from the meeting can be found at: www.treatmentactiongroup.org/hiv/nhas.

**TAG Helps Launch HCV Global Treatment Access Movement**

Dozens of new drugs are in the pipeline, and the standard of care is rapidly evolving toward short-course, highly effective interferon-free treatment. These therapeutic advances—and rising death rates from HCV-associated complications—have created momentum for a global treatment access movement.

TAG’s Director of International Hepatitis/HIV Policy and Advocacy, Karyn Kaplan, is providing leadership and technical assistance to activist allies and coalitions working to create and increase access to HCV prevention, care, and treatment.

TAG is a key stakeholder in all matters related to HCV treatment. TAG’s connections with activist allies, researchers, policy makers, foundations, patient groups, academic institutions, regulatory agencies, and the pharmaceutical industry have made it possible for us to organize productive high-level meetings, alter policies, and help advance a strong research advocacy agenda.

In 2012, TAG’s Hepatitis/HIV Project:

- Brought together more than 50 international activists at the International AIDS Conference for the first-ever strategy meeting on HCV treatment access;
- Colaunched, on World Hepatitis Day, the Washington Call for Access to HCV Diagnostics, Treatment, and Care for All!, an advocacy platform for the international HCV treatment access movement;
- Cosponsored a multi-stakeholder meeting to discuss a series of barriers to HCV treatment access in low- and middle-income countries (LMICs), and strategized on ways to surmount them;
- Participated in the development of HCV treatment guidelines for LMICs;
- Fought for HCV drug development inclusive of high-prevalence groups, many at risk for liver disease progression: HIV/HCV coinfected people, current and former injecting drug users, people with advanced liver disease, African Americans, Latinos/Latinas, and transplant candidates and recipients;
- Fought for early access initiatives to provide potentially lifesaving treatment access; and
- Coordinated an international group of HCV treatment activists to give the community a strong voice in HCV drug development.

**Toward an HIV Cure**

In March 2012, TAG, the AIDS Treatment Activists Coalition (ATAC), and Project Inform cosponsored a workshop to discuss how community input and advocacy can accelerate research and speed the development of a cure for HIV/AIDS. Sixty-one people attended, including seven representatives from the drug and biologics divisions of the U.S. Food and Drug Administration (FDA), a regulator from Health Canada, representatives from the International AIDS Society (IAS) and several pharmaceutical companies, academic researchers, and many community advocates (both U.S.-based and international). Speakers included representatives from the AIDS Clinical Trials Group, the three recently funded Martin Delaney Collaboratories, Gilead, Sangamo BioSciences, City of Hope, and the University of Pennsylvania.

As part of an ongoing collaboration with the IAS’s “Towards an HIV Cure” advocacy effort, TAG also cosponsored a cure research symposium in Washington, D.C., in July and participated in the launch of the IAS Global Scientific Strategy for the field. TAG organized a presymposium workshop for community attendees with the aim of increasing cure-research literacy, and hosted a similar event as a satellite to the subsequent International AIDS Conference.

TAG continued to provide ongoing coverage of HIV cure research in publications such as TAGline, its annual Pipeline Report, and via the organization’s website and Michael Palm HIV Basic Science, Vaccines, and Prevention Project Weblog. The TAG website includes a frequently updated page listing cure-related research resources and clinical trials (www.treatmentactiongroup.org/cure).
First New TB Drug on the Market in 40 Years

TAG was part of several major victories in the global fight against TB in 2012. Among the most important achievements of the year was the Zeroes Campaign, a bold new strategy that calls for global action to achieve zero TB deaths, zero new TB infections, and zero suffering and stigma. The campaign, which launched in May 2012, galvanized the global community with support from over 317 individuals and 146 organizations, including the Stop TB Partnership, which endorsed it as part of its operational strategy, the Global Plan to Stop TB 2011–2015.

TAG also played a critical role in raising awareness of childhood TB and in calling for it to be included in statistical data collected by the World Health Organization. In January 2012, TAG held a federal advocacy meeting on childhood TB, which spurred a call to action among domestic advocates and policy makers to increase funding and support for childhood TB R&D activities. TAG worked with international advocates to document pediatric drug-resistant TB globally and develop a road map for advocacy, and co-hosted a congressional TB briefing to highlight childhood TB advocacy.

The Community Research Advisory Group (CRAG) to the Centers for Disease Control and Prevention’s Tuberculosis Trials Consortium continues to grow as a respected advisory body. TAG and the CRAG have been instrumental in developing the Good Participatory Practice Guidelines for TB Drug Trials (GPP-TB), which was recently acknowledged by the Presidential Commission for the Study of Bioethical Issues. The team also codeveloped a proposal to implement the GPP-TB, which is likely to receive National Institutes of Health (NIH) funding in 2013.

The Global TB Community Advisory Board (TB CAB), a group of highly skilled activists from nine countries, celebrated its one-year anniversary in 2012. With support from TAG, the TB CAB played an active role in TB drug development, including advocating for compassionate use programs for new TB drugs entering the market.

The culminating event of 2012 was the FDA’s accelerated approval of the first new TB drug from a new drug class in over 40 years. Regulatory approval of bedaquiline, a new drug to treat multidrug-resistant TB, is an enormous win for the global TB community. With 1.4 million TB deaths annually, the need for new drugs has never been more urgent. As new drugs enter the market, TAG will continue to work tirelessly to ensure that these essential medicines reach all those in need.

Mounting Fiscal and Political Pressures Threaten Safety Nets

TAG’s policy program in Washington, D.C., has continued to make measurable progress in the fight for increased HIV, TB, and hepatitis funding, education, and advocacy despite mounting fiscal and political challenges. Budgetary cuts, notably the sequestration enacted in March 2013, threaten the fragile safety-net infrastructure for low-income and marginalized people living with HIV in the United States.

Over the past year, TAG advocated for the creation of the first-ever TB congressional caucus, presented at three congressional briefings, organized a number of high-profile community advocacy activities, and led the development of a number of sign-on letters, position statements, declarations, press releases, and reports. TAG strengthened critical working relationships with HIV and TB/HIV community members, civil-society partners, as well as key administration and congressional stakeholders with influence over funding and policy decisions.
$2,500 – $4,999
M. Lee Garrison
Global Alliance for TB Drug Development
Kevin & Neil Goetz/Screen Engine LLC
Merck & Co.
Rabin Martin
Ted Snowdon
Douglas Wirth/Amida Care

$1,000 – $2,499
Aeras Global TB Vaccine Foundation
Benjamin, Christine, & Darius Anagnos
David Arbuthnot
Beth Israel Medical Center
Bob Bronzo
John Caldwell & Zane Blaney
Richard Cardillo “In Memory of Peter Franklin Diffly Jr.”
Dr. & Mrs. Charles C. J. Carpenter
Tim & Mary Casey
Lawrence Chanen & Jack Burkharter
The Corkery Group
Stephen M. Dillon, MD
Randall G. Drain
John F. Duane
Margaret Dudley “On behalf of Texas HCV Coalition for the Cure”
The Durst Organization
Marcus Edward & Ken O’Neill
Breken & Carter Elwood-Ethington
Nora Ephron & Nicholas Pileggi Foundation
f u s e/ Madison Square Garden
David France & Jonathan Starch
Steven & Judith Gluckstein
Richard & Judith Harrington
Barbara Hughes & Andrea Benzacar
The Johns Hopkins University
Kenneth Cole Foundation
Noel E. D. Kirnon & Michael D. Paley
Robert J. McAlpin & Alberto Blanquiel
Anthony & Celeste Meier
Kenneth T. Monteiro & Leo J. Blackman
Jason Oscher & Richard Schubel
Earl L. Plante
Sara Rafsky & Babette E. Krolik
Frank Rappo
RESULTS Educational Fund
David Rosenauer & Rex Walker Fund of Stonewall Community Foundation
Dr. Bruce R. Schackman & Edward K. Sikov
Evon Schwartz & Robert Fitterman
Samuel J. Silling & Curtis Lyles
Dr. Peter Small & Dr. Delaney Ruston
Peter Staley & Gary Schwartz
Stanley H. Tomchin
Universitätsklinik Bonn
W. Kirk Wallace & Mark M. Sexton Fund of Stonewall Community Foundation
Carolyn & Bill Wolle
Andrew D. Zacks Foundation

$250 – $499
Lydia M. Ashcraft
Jody Mark Barnofsky & Charlotte M. Litman
Alvin H. Baum Jr.
William Berger & Stephen Miller
Andrew Berman
Jamie Bernstein
Laura Blair
Lynne Brown
Eli & Jallie Camhi
David L. Caplan
Stephanie Cowles
Mrs. Denise B. Dailey
Scott Dainton

$250 – $499
Carl Berg, PhD & Judith Green, PhD
Karen Bronzo & Jefferson Rabb
Scott Campbell “In Memory of Spencer Cox”
James F. Capalino/Capalino + Company
Catholic Relief Services
Paula Chafin & Megan Lewis
George Cominski & John Turner
Dr. Ellen C. & Mike Cooper
Ronald D’Angelo
Ariane Dar/Marin Community Foundation
Edward J. Davis & Thomas D. Phillips
Simon Donnan & Jonathan Adler
Michelle & Andre Dore/The InLink Group LLC
Dorothy Londen Foundation/Lionel Lerner
Hon. Thomas K. Duane & Louis Weber
Jim Edwards
Gene Fark
Ford Foundation
Evan Galan
Kenneth Goody & Tod Moffett/Ken Goody Fund of Stonewall Community Foundation
Perry & Robert Halkitis
Mark Hamilton
Chris Harrington & Daphne Powell
Mark Harrington “In Memory of Spencer Cox”
Melanie Havelin
Dr. Marjorie Hill
Karen Hird
J. Drew Hodges
Jenny Holzer
Kevin Jennings & Jeff Davis
Martin & Beth L. Katz
Paul E. Kennedy
Rev. Charles King/Housing Works
Babette E. Krolik & Harry P. Greenwald
“In Honor of Sara Rafsky & Mark Harrington”
Sarah F. Lazin “In Memory of Parsla Berzins”
David C. Levine
Albert S. Messina “In Honor of Richard A. Jacobs”
Mirla & George Morrison
Laura A. Morrison
Robert J. Munk
National Convention Services/Debra Hoefler
Robert Pini & Michael Boodro
Project Inform
Catherine M. Randolph “In Memory of Peter Franklin Diffly Jr.”
David A. Rimple & Paul Teixeira
Ron & Cynthia Rose/Rose Family Charity Fund
Whitney M. Sogol
Harry Stahl
Mante Steinman
Paul Warren
William F. Ryan Community Health Network

$250 – $499
Lynda M. Dee, Esq.
S. David Deitcher
Kevin DeLeage
John Deyling
Dinowitz & Bove
Peter Morris Dixon
Carol & John Field Fund of Fidelity
Charitable Gift Fund
Sabina Fila
Ruth K. Finkelstein & BC Craig
Kenneth Forntaro
Charles Franchino
Steven M. Frank & Dr. Elizabeth Powell
Frederic W. Cook & Co.
Friends of Assemblymember Deborah Glick
Alan Getz
Leslie Asako Gladisjo
Peter Goldman
Barry Goralnick & Keith Gordon
Robert A. Guida, MD, PC
Dr. Roy M. “Trip” Guillem & Tom Beckett
David Hansell
Kenneth Hecht
Frank Hettig
Hospita1 of St. Raphael One For All Fund
IAVI International AIDS Vaccine Initiative
Ken Jackers
Claude LaFlamme
John Patrick Lanasra
Joe Lauretano
Burt R. Lazarin
Andrew Lazin “In Memory of Parsla Berzins”
Stanton J. Lovenworth
James Martin
F Joseph McConnell & Erik Haagensen
Florent Morellet
Congressman Jerrold Nadler
Scott Newman
Donna M. Pauldine “In Memory of Jeff Palladino”
Leslie Fay Pomerantz
Troy Reinhardt
Scott D. Robbe
Greig Sargeant
Lyle Saunders
Dennis & Debra Scholl
Stephen Shawn & Sunita Viswanath
George Sheer
Virginia Shubert
Sue Simon
Margie & Mart Steinberg
Antonio Strazzullo
Anthony Stuart & Will Rogers
Tiffany & Co.
Keith S. Tobin, MD
United Way of New York City
Mitchell Warren/AVAC: Global Advocacy for HIV Prevention
Adam Weitz “In Memory of George Osterman”
Thomas Wilczak “In Memory of Jeffrey Kucharski”
P. Forrest Williams Jr.
Anthony Zisa

Plus donations from an additional 309 contributors

In-Kind Donations
A/X Armani Exchange
Marc Berman/Club 570
Tiffany & Co.

the watsons

Contributors
## TAG FINANCIALS 2012

### STATEMENTS OF FINANCIAL POSITION

#### ASSETS

<table>
<thead>
<tr>
<th>Category</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,399,659</td>
<td>$1,319,417</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>1,091,547</td>
<td>1,038,191</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>20,523</td>
<td>5,789</td>
</tr>
<tr>
<td>Donated inventory</td>
<td>255,500</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td>$2,767,229</td>
<td>$2,605,897</td>
</tr>
<tr>
<td>Property and equipment – net of accumulated depreciation</td>
<td>41,707</td>
<td>30,130</td>
</tr>
<tr>
<td>Security deposits</td>
<td>43,015</td>
<td>43,015</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$2,851,951</td>
<td>$2,679,042</td>
</tr>
</tbody>
</table>

#### LIABILITIES AND NET ASSETS

<table>
<thead>
<tr>
<th>Category</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$25,636</td>
<td>$23,023</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td>25,636</td>
<td>23,023</td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>1,761,603</td>
<td>1,656,206</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>1,064,712</td>
<td>999,813</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td>2,826,315</td>
<td>2,656,019</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td>$2,851,951</td>
<td>$2,679,042</td>
</tr>
</tbody>
</table>

#### STATEMENTS OF CASH FLOWS

<table>
<thead>
<tr>
<th>Category</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase in net assets</td>
<td>$170,296</td>
<td>$209,552</td>
</tr>
<tr>
<td>Adjustments to reconcile increase in net assets to net cash provided by operating activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>14,450</td>
<td>26,452</td>
</tr>
<tr>
<td>Donated inventory received</td>
<td>(130,000)</td>
<td>(70,000)</td>
</tr>
<tr>
<td>Direct benefit to event participants</td>
<td>117,000</td>
<td>28,000</td>
</tr>
<tr>
<td><strong>(Increase) Decrease in current assets</strong></td>
<td>(53,356)</td>
<td>39,840</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>(14,734)</td>
<td>1,728</td>
</tr>
<tr>
<td>Security deposits</td>
<td>–</td>
<td>(22,361)</td>
</tr>
<tr>
<td><strong>(Decrease) Increase in current liabilities</strong></td>
<td>2,613</td>
<td>20,163</td>
</tr>
<tr>
<td><strong>NET CASH PROVIDED BY OPERATING ACTIVITIES</strong></td>
<td>$106,269</td>
<td>$233,374</td>
</tr>
<tr>
<td>Cash flows from investing activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of property and equipment</td>
<td>(26,027)</td>
<td>(21,213)</td>
</tr>
<tr>
<td><strong>NET CASH USED IN INVESTING ACTIVITIES</strong></td>
<td>(26,027)</td>
<td>(21,213)</td>
</tr>
<tr>
<td><strong>NET INCREASE IN CASH BALANCE</strong></td>
<td>80,242</td>
<td>212,161</td>
</tr>
<tr>
<td>CASH, BEGINNING OF YEAR</td>
<td>1,319,417</td>
<td>1,107,256</td>
</tr>
<tr>
<td><strong>CASH, END OF YEAR</strong></td>
<td>$1,399,659</td>
<td>$1,319,417</td>
</tr>
</tbody>
</table>

**Supplementary disclosures of cash flow information**

- Donated goods and services: $158,951, $110,624
STATEMENTS OF ACTIVITIES

REVENUE AND SUPPORT

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>2012 Total</th>
<th>2011 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donations</td>
<td>$ 66,022</td>
<td>–</td>
<td>$ 66,022</td>
<td>$ 53,809</td>
</tr>
<tr>
<td>Grants</td>
<td>586,328</td>
<td>1,107,212</td>
<td>1,693,540</td>
<td>1,659,606</td>
</tr>
<tr>
<td>Special event income</td>
<td>365,513</td>
<td>–</td>
<td>365,513</td>
<td>215,689</td>
</tr>
<tr>
<td>Travel and other reimbursement</td>
<td>15,503</td>
<td>–</td>
<td>15,503</td>
<td>34,327</td>
</tr>
<tr>
<td>Interest and dividend income</td>
<td>4,687</td>
<td>–</td>
<td>4,687</td>
<td>5,851</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>1,042,313</td>
<td>(1,042,313)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>TOTAL REVENUE AND SUPPORT</strong></td>
<td><strong>$ 2,080,366</strong></td>
<td><strong>$ 64,899</strong></td>
<td><strong>$ 2,145,265</strong></td>
<td><strong>$ 1,969,282</strong></td>
</tr>
</tbody>
</table>

EXPENSES

Program services
- HIV Project: $128,534, $ –, $128,534, $141,132
- Cure Project: 163,552, –, 163,552, 162,746
- Hepatitis and HIV Project: 229,342, –, 229,342, 257,057
- Tuberculosis and HIV Project: 1,052,649, –, 1,052,649, 843,927
- Communications and Advocacy Project: 76,024, –, 76,024, 34,484
- U.S. and Global Health Policy Project: 26,759, –, 26,759, 61,266

**TOTAL PROGRAM EXPENSES** | $ 1,676,860 | – | $ 1,676,860 | $ 1,500,612 |

Management and general: 143,039, –, 143,039, 140,076

Fundraising: 155,070, –, 155,070, 119,042

**TOTAL SERVICES EXPENSES** | $ 1,974,969 | – | $ 1,974,969 | $ 1,759,730 |

Increase in net assets: 105,397, 64,899, 170,296, 209,552

Net assets, beginning of year: 1,656,206, 999,813, 2,656,019, 2,446,467

**NET ASSETS, END OF YEAR** | $ 1,761,603 | $ 1,064,712 | $ 2,826,315 | $ 2,656,019 |
THE 2012 PALM DONOR CIRCLE

With TAG’s Accelerating Research to Cure AIDS Campaign in Red

The Palm Donor Circle is TAG’s major donor program, named in honor of philanthropist and TAG supporter Michael Palm (1951–1998). Members of the Palm Donor Circle made individual donations of $1,000 or more in 2012.

Benjamin, Christine, & Darius Anagnos
David Arbuthnot
Bob Bronzo
John Caldwell & Zane Blaney
Timothy Callis
Richard Cardillo
Dr. & Mrs. Charles C. J. Carpenter
Tim & Mary Casey
Lawrence Chanen & Jack Burghalter
Eileen Cohen
Kenneth & Maria Cuomo Cole
Mark Emerson Collins, Esq.
David Corkery
Richard A. & Barbara Knowles Debs
Beth Rudin DeWoody
Stephen M. Dillon, M.D.
Randall G. Drain
John F. Duane
Margaret Dudley
Douglas Durst
Marcus Edward & Ken O’Neill
Elton John AIDS Foundation
Breken & Carter Elwood-Etherington
Nora Ephron & Nicholas Pileggi Foundation
Joy Episalla & Carrie Yamaoka
Donna Flax
David France & Jonathan Starch
M. Lee Garrison
Dr. Michael F. Giordano
Steven & Judith Gluckstein
Kevin & Neil Goetz
Addie Guttag
Richard & Judith Harrington
Barbara Hughes & Andrea Benzacar
Noel E. D. Kirnon & Michael D. Paley

Charles A. Ledray
Michael K. Longacre
Richard M. Lynn & Joseph Evall
Alby P. Maccarone Jr.
Christy & John Mack
Robert J. McLain & Alberto Blanquel
Anthony & Celeste Meier
Kenneth T. Monteiro & Leo J. Blackman
Robert E. Monteleone
Fraser D. “Skip” Mooney
Mark O’Donnell & James E. McGreevey
Jason Osher & Richard Schubel
Earl L. Plante
Steve Rabin
Sara Rafsky & Babette E. Krolik
Frank Rappa
David C. Rich
David Rosenauer & Rex Walker
Jamie Saakvitne & Daniel Chow
Dr. Bruce R. Schackman & Edward K. Sikov
Evan Schwartz & Robert Fitterman
Marvin Shulman
David Sigal & Brad Hoyt
Ellen V. & Gerald R. Sigal
Samuel J. Silling & Curtis Lyles
Dr. Peter Small & Dr. Delaney Ruston
Ted Snowden
Peter Staley & Gary Schwartz
Jon Styker
Joy A. Tomchin
Stanley H. Tomchin
W. Kirk Wallace & Mark M. Sexton
Sally G. Williams Blanco & P. Forrest Williams
Douglas Wirth
Andrew D. Zacks

TAG BE INVOLVED

Contribute
TAG welcomes donations from individuals who want to see the AIDS research agenda remain responsive to the needs of all people living with HIV.

Make a tax-deductible gift now:
www.treatmentactiongroup.org/support

Join TAG’s Board
TAG is always seeking new board members. If you are looking for a great place to invest your time and talents, please call Barbara Hughes, TAG Board President, to learn more. Call 212.253.7922, or e-mail barbara.hughes@treatmentactiongroup.org.

About TAG
Treatment Action Group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end AIDS.

TAG is a nonprofit, tax-exempt 501(c)(3) organization. EIN 13-3624785

BOARD OF DIRECTORS
PRESIDENT
Barbara Hughes
SECRETARY AND TREASURER
Laura Morrison
Joy Episalla
Roy Gulick, MD
Kevin Goetz
Richard Lynn, PhD
Alby Maccarone
Robert Monteleone
Jason Osher
Earl L. Plante
Frank Rappa
Frank Selvaggi
David Sigal
Whitney M. Sogol
Monte Steinman
EXECUTIVE DIRECTOR
Mark Harrington
DEPUTY EXECUTIVE DIRECTOR
Scott Morgan
EDITORIAL DIRECTOR
Andrea Benzacar
COMMUNICATIONS AND ADVOCACY DIRECTOR
Lei Chou
TB/HIV PROJECT DIRECTOR
Colleen Daniels
TB/HIV PROJECT OFFICER
Mike Frick
HIV PROJECT DIRECTOR AND TAGLINE EDITOR
Tim Horn
MICHAIL PALM BASIC SCIENCE, VACCINES, AND PREVENTION PROJECT COORDINATOR
Richard Jefferys
SENIOR ASSOCIATE FOR U.S. AND GLOBAL HEALTH POLICY
Karyn Kaplan
TB/HIV PROJECT ASSISTANT DIRECTOR
Erica Lessem
ADMINISTRATOR
Joseph McConnell
TB/HIV ASSISTANT PROJECT OFFICER
Lindsay McKenna
HEPATITIS/HIV PROJECT DIRECTOR
Tracy Swan

TAG is a nonprofit, tax-exempt 501(c)(3) organization. EIN 13-3624785

TREATMENT ACTION GROUP
261 Fifth Avenue, Suite 2110
New York, NY 10016
Tel 212.253.7922
Fax 212.253.7923
tag@treatmentactiongroup.org
www.treatmentactiongroup.org

About TAG
Treatment Action Group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end AIDS.